These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15470272)

  • 41. Highly active antiretroviral therapy-related mechanisms of endothelial and platelet function alterations.
    Gresele P; Falcinelli E; Momi S; Francisci D; Baldelli F
    Rev Cardiovasc Med; 2014; 15 Suppl 1():S9-20. PubMed ID: 24987863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly active antiretroviral therapy and the cardiovascular system: the heart of the matter.
    Barbaro G
    Pharmacology; 2003 Dec; 69(4):177-9. PubMed ID: 14624056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of dyslipidaemia in HIV-infected persons.
    Manuel O; Thiébaut R; Darioli R; Tarr PE
    Expert Opin Pharmacother; 2005 Aug; 6(10):1619-45. PubMed ID: 16086650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular disease in HIV infection.
    Palella FJ; Phair JP
    Curr Opin HIV AIDS; 2011 Jul; 6(4):266-71. PubMed ID: 21546831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients].
    Ena J; Benito C; Llácer P; Pasquau F; Amador C
    Med Clin (Barc); 2004 May; 122(19):721-6. PubMed ID: 15171905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular risk assessment in antiretroviral-naïve HIV patients.
    Maggi P; Quirino T; Ricci E; De Socio GV; Gadaleta A; Ingrassia F; Perilli F; Lillo A; Bonfanti P
    AIDS Patient Care STDS; 2009 Oct; 23(10):809-13. PubMed ID: 19824809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular effects of HAART in infants and children of HIV-infected mothers.
    Zareba KM; Lavigne JE; Lipshultz SE
    Cardiovasc Toxicol; 2004; 4(3):271-9. PubMed ID: 15470274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular disease associated with human immunodeficiency virus: a review.
    Costa LA; Almeida AG
    Rev Port Cardiol; 2015; 34(7-8):479-91. PubMed ID: 26162286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV and cardiovascular risk factors.
    Falusi OM; Aberg JA
    AIDS Read; 2001 May; 11(5):263-8. PubMed ID: 11392695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
    Smith KY
    J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
    Patroni A; Torti C; Tomasoni L; Quiros Roldan E; Bertelli D; Puoti M; Cadeo GP; Sleiman I; Tinelli C; Carosi G; Castelli F
    HIV Clin Trials; 2002; 3(6):451-61. PubMed ID: 12501128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
    Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G
    Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.